The FDA NIH Biomarkers, EndpointS, and other Tools (BEST) resource in neuro-oncology

被引：103

作者：

Cagney, Daniel N. ^{[1
]}

Sul, Joohee ^{[2
]}

Huang, Raymond Y. ^{[3
]}

Ligon, Keith L. ^{[4
]}

Wen, Patrick Y. ^{[5
]}

Alexander, Brian M. ^{[1
]}

机构：

[1] Harvard Med Sch, Dana Farber Brigham & Womens Canc Ctr, Dept Radiat Oncol, Boston, MA USA

[2] US FDA, Off Hematol & Oncol Prod, Ctr Drug Evaluat & Res, Silver Spring, MD USA

[3] Harvard Med Sch, Brigham & Womens Hosp, Dept Radiol, Boston, MA USA

[4] Harvard Med Sch, Brigham & Womens Hosp, Dept Pathol, Boston, MA USA

[5] Harvard Med Sch, Dana Farber Brigham & Womens Canc Ctr, Ctr Neurooncol, Boston, MA USA

来源：

NEURO-ONCOLOGY | 2018年 / 20卷 / 09期

关键词：

BEST glossary; biomarkers; endpoints; glioma; outcomes; PROGRESSION-FREE SURVIVAL; HIGH-GRADE GLIOMAS; NEWLY-DIAGNOSED GLIOBLASTOMA; BRAIN-TUMOR CELLS; PHASE-III TRIAL; OF-THE-ART; PERFORMANCE STATUS; CLINICAL-TRIALS; ISOCITRATE DEHYDROGENASE; OLIGODENDROGLIAL TUMORS;

D O I：

10.1093/neuonc/nox242

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In early 2016, the FDA and the National Institutes of Health (NIH) published the first version of the glossary included in the Biomarkers, EndpointS, and other Tools (BEST) resource. 1 The BEST glossary was constructed to harmonize and clarify terms used in translational science and medical product development and to provide a common language used for communication by those agencies. It is considered a "living" document that will be updated in the future. This review will discuss the main biomarker and clinical outcome categories contained in the BEST glossary as they apply to neuro-oncology, as well as the overlapping and hierarchical relationships among them.

引用

页码：1162 / 1172

页数：11

共 84 条

[1] THE EUROPEAN-ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER QLQ-C30 - A QUALITY-OF-LIFE INSTRUMENT FOR USE IN INTERNATIONAL CLINICAL-TRIALS IN ONCOLOGY [J].

AARONSON, NK ;

AHMEDZAI, S ;

BERGMAN, B ;

BULLINGER, M ;

CULL, A ;

DUEZ, NJ ;

FILIBERTI, A ;

FLECHTNER, H ;

FLEISHMAN, SB ;

DEHAES, JCJM ;

KAASA, S ;

KLEE, M ;

OSOBA, D ;

RAZAVI, D ;

ROFE, PB ;

SCHRAUB, S ;

SNEEUW, K ;

SULLIVAN, M ;

TAKEDA, F .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (05) :365-376

[2] The Potential of Radiomic-Based Phenotyping in PrecisionMedicine A Review [J].

Aerts, Hugo J. W. L. .

JAMA ONCOLOGY, 2016, 2 (12) :1636-1642

[3] miR-21 in the Extracellular Vesicles (EVs) of Cerebrospinal Fluid (CSF): A Platform for Glioblastoma Biomarker Development [J].

Akers, Johnny C. ;

Ramakrishnan, Valya ;

Kim, Ryan ;

Skog, Johan ;

Nakano, Ichiro ;

Pingle, Sandeep ;

Kalinina, Juliya ;

Hua, Wei ;

Kesari, Santosh ;

Mao, Ying ;

Breakefield, Xandra O. ;

Hochberg, Fred H. ;

Van Meir, Erwin G. ;

Carter, Bob S. ;

Chen, Clark C. .

PLOS ONE, 2013, 8 (10)

[4] Adult Glioblastoma [J].

Alexander, Brian M. ;

Cloughesy, Timothy F. .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (21) :2402-+

[5] Progression-free survival: too much risk, not enough reward? [J].

Alexander, Brian M. ;

Trippa, Lorenzo .

NEURO-ONCOLOGY, 2014, 16 (05) :615-616

[6]

Alexander BM, 2011, EXPERT REV NEUROTHER, V11, P1399, DOI [10.1586/ERN.11.134, 10.1586/ern.11.134]

[7]

[Anonymous], 2016, BEST (Biomarkers, EndpointS, and other Tools) Resource

[8] Net Clinical Benefit Analysis of Radiation Therapy Oncology Group 0525: A Phase III Trial Comparing Conventional Adjuvant Temozolomide With Dose-Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma [J].

Armstrong, Terri S. ;

Wefel, Jeffrey S. ;

Wang, Meihua ;

Gilbert, Mark R. ;

Won, Minhee ;

Bottomley, Andrew ;

Mendoza, Tito R. ;

Coens, Corneel ;

Werner-Wasik, Maria ;

Brachman, David G. ;

Choucair, Ali K. ;

Mehta, Minesh .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (32) :4076-+

[9] Risk analysis of severe myelotoxicity with temozolomide: The effects of clinical and genetic factors [J].

Armstrong, Terri S. ;

Cao, Yumei ;

Scheurer, Michael E. ;

Vera-Bolanos, Elizabeth ;

Manning, Rochelle ;

Okcu, Mehmet F. ;

Bondy, Melissa ;

Zhou, Renke ;

Gilbert, Mark R. .

NEURO-ONCOLOGY, 2009, 11 (06) :825-832

[10]

Armstrong TS, ONC NURS FOR 2005

← 1 2 3 4 5 6 7 8 9 →